Hemodiafiltration beyond the CONVINCE trial

Giovanni F M Strippoli(The University of Sydney), Rümeyza Kazancıoğlu(Bezmiâlem Vakıf Üniversitesi), Vasileios C. Pezoulas(University of Ioannina), J M Jolanta Malyszko(Medical University of Warsaw), J Hegbrant(Lund University), Sagar Nigwekar(Harvard University), Michael Anger(Fresenius Medical Care (United States)), Dimitrios I Fotiadis(University of Ioannina), Allison Jaure(The University of Sydney), Krister Cromm(Humboldt-Universität zu Berlin), Nikolaos Tachos(University of Ioannina), Felix Fischer(Humboldt-Universität zu Berlin)
Clinical Kidney Journal
April 15, 2026
10.1093/ckj/sfag115
Cited by 1

Related Papers

Effect of Hemodiafiltration or Hemodialysis on Mortality in Kidney Failure
|New England Journal of Medicine|2023|287
Synthetic data generation methods in healthcare: A review on open-source tools and methods
|Computational and Structural Biotechnology Journal|2024|192
Benefits and harms of high-dose haemodiafiltration versus high-flux haemodialysis: the comparison of high-dose haemodiafiltration with high-flux haemodialysis (CONVINCE) trial protocol
|BMJ Open|2020|67
The CONVINCE randomized trial found positive effects on quality of life for patients with chronic kidney disease treated with hemodiafiltration
|Kidney International|2024|48
CONVINCE in the context of existing evidence on haemodiafiltration
|Nephrology Dialysis Transplantation|2022|28